AGL 37.90 Increased By ▲ 0.33 (0.88%)
AIRLINK 132.20 Decreased By ▼ -0.30 (-0.23%)
BOP 5.61 Decreased By ▼ -0.03 (-0.53%)
CNERGY 3.80 Increased By ▲ 0.03 (0.8%)
DCL 8.74 Decreased By ▼ -0.13 (-1.47%)
DFML 40.72 Decreased By ▼ -0.28 (-0.68%)
DGKC 88.25 Decreased By ▼ -1.91 (-2.12%)
FCCL 35.35 Increased By ▲ 0.27 (0.77%)
FFBL 66.30 Decreased By ▼ -0.20 (-0.3%)
FFL 10.37 Increased By ▲ 0.22 (2.17%)
HUBC 109.08 Increased By ▲ 2.68 (2.52%)
HUMNL 14.22 Increased By ▲ 0.82 (6.12%)
KEL 4.86 No Change ▼ 0.00 (0%)
KOSM 7.01 Increased By ▲ 0.16 (2.34%)
MLCF 42.12 Increased By ▲ 0.32 (0.77%)
NBP 59.71 Increased By ▲ 1.13 (1.93%)
OGDC 184.69 Increased By ▲ 3.44 (1.9%)
PAEL 25.55 Decreased By ▼ -0.15 (-0.58%)
PIBTL 5.86 Increased By ▲ 0.03 (0.51%)
PPL 148.50 Increased By ▲ 0.10 (0.07%)
PRL 23.15 Decreased By ▼ -0.07 (-0.3%)
PTC 16.36 Increased By ▲ 1.12 (7.35%)
SEARL 68.20 Decreased By ▼ -0.59 (-0.86%)
TELE 7.30 Increased By ▲ 0.06 (0.83%)
TOMCL 35.85 Decreased By ▼ -0.15 (-0.42%)
TPLP 7.54 Increased By ▲ 0.14 (1.89%)
TREET 14.20 Decreased By ▼ -0.04 (-0.28%)
TRG 50.95 Increased By ▲ 0.10 (0.2%)
UNITY 26.49 Increased By ▲ 0.09 (0.34%)
WTL 1.22 Increased By ▲ 0.01 (0.83%)
BR100 9,774 Increased By 5.9 (0.06%)
BR30 29,763 Increased By 362.7 (1.23%)
KSE100 92,093 Increased By 154.8 (0.17%)
KSE30 28,724 Decreased By -20.1 (-0.07%)
Pakistan

Pakistan to receive China's CanSino COVID-19 vaccine for commercial sale this week

  • It is expected that the first 10,000 doses will reach Pakistan on March 25, and 100,000 more doses by next month
  • Trial results show that CanSino vaccine is 65.7 percent effective in preventing symptomatic COVID-19 cases and has 90.98 percent success rate in stopping severe infections
Published March 22, 2021

(Karachi) Pakistan is all set to receive shipments of China’s CanSino Biologics coronavirus vaccine for commercial sale this week, local media reported on Monday.

An official of AJ Pharma said it is expected that the first 10,000 doses will reach Pakistan on March 25, and 100,000 more doses by next month. He added that 200,000 CanSino vaccine doses will be shipped in May.

Earlier, health officials said the single-dose Chinese vaccine could be administered to people of all ages as it was found effective among people from 18 to 80 plus years of age during trials in Pakistan and other countries of the world.

They disclosed that the CanSino Biologics Inc.’s vaccine would also be ‘manufactured partially in Pakistan,’ following its successful conclusion of trials at five leading health institutions in the country.

The registration board of Pakistan’s Drug Regulatory Authority of Pakistan (DRAP) had given emergency use authorization to CanSino Biologics’s single-dose vaccine in the second week of February 2021 after the Chinese manufacturer released interim efficacy results from a multi-country trial, which included Pakistan, showing 65.7 percent efficacy in preventing symptomatic COVID-19 cases and a 90.98 percent success rate in stopping severe infections.

Comments

Comments are closed.